Palisade Bio (NASDAQ: PALI) boosts R&D spend to advance PALI-2108

Rhea-AI Filing Summary

Palisade Bio reported first quarter 2026 results and highlighted progress of its lead IBD candidate, PALI-2108. The company completed Phase 1a/1b studies with favorable safety, target engagement in ileum and colon tissue, and early clinical activity, and is preparing Phase 2 trials in ulcerative colitis and Crohn’s disease starting in 3Q 2026 and 1Q 2027, respectively.

Research and development expenses rose to $6.4 million and general and administrative expenses to $4.4 million, driving a net loss of $9.6 million for the quarter. Palisade ended March 31, 2026 with $132.6 million in cash and cash equivalents and expects this to fund operations through Phase 2 efficacy readouts for PALI-2108 in 2027 and early 2028.

Positive

• Strong cash position and runway: Cash and cash equivalents of $132.6 million as of March 31, 2026 are expected to fund operations through Phase 2 primary efficacy readouts for PALI-2108 in ulcerative colitis and Crohn’s disease in 2027 and early 2028.

Negative

• Substantially higher operating loss: Net loss increased to $9.6 million for the quarter ended March 31, 2026, compared with $2.2 million a year earlier, driven by sharply higher R&D and G&A expenses as clinical development and corporate infrastructure expanded.

Insights

Biotech equity analyst

Cash runway supports costly Phase 2 IBD program build-out.

Palisade Bio is transitioning PALI-2108 from Phase 1 to Phase 2 in ulcerative colitis and Crohn’s disease, with multiple trials planned from 3Q 2026 through 1Q 2027. Phase 1a/1b data showed target engagement in ileal and colon tissue with a favorable safety profile.

Quarterly spending increased sharply as development scaled. Research and development expenses reached $6.4M and general and administrative expenses $4.4M, widening the net loss to $9.6M for the quarter. This reflects higher clinical, CMC and employee-related costs including stock-based compensation.

The company reported cash and cash equivalents of $132.6M as of March 31, 2026, expecting this to fund operations through Phase 2 primary efficacy readouts in UC in 2H 2027 and Crohn’s disease in early 2028. Subsequent filings may provide updated views on spending pace and timing of these milestones.

8-K Event Classification

2 items: 2.02, 9.01

2 items

Item 2.02 Results of Operations and Financial Condition Financial

Disclosure of earnings results, typically an earnings press release or preliminary financials.

Item 9.01 Financial Statements and Exhibits Exhibits

Financial statements, pro forma financial information, and exhibit attachments filed with this report.

Key Figures

Cash and cash equivalents: $132.6M Net loss: $9.6M Research and development expense: $6.4M +5 more

8 metrics

Cash and cash equivalents $132.6M As of March 31, 2026

Net loss $9.6M Three months ended March 31, 2026

Research and development expense $6.4M Three months ended March 31, 2026

General and administrative expense $4.4M Three months ended March 31, 2026

Total assets $133.3M As of March 31, 2026

Total liabilities $6.0M As of March 31, 2026

Operating cash used $3.9M Net cash used in operating activities, Q1 2026

Proceeds from common stock issuance $3.25M Financing cash flows, Q1 2026

Key Terms

PDE4 inhibitor prodrug, fibrostenotic Crohn’s disease, Phase 2 primary efficacy readout, stock-based compensation, +1 more

5 terms

PDE4 inhibitor prodrug medical

"a next-generation oral PDE4 inhibitor prodrug designed to improve pharmacology, tolerability and convenience"

fibrostenotic Crohn’s disease medical

"Phase 1b fibrostenotic Crohn’s disease (“FSCD”) cohort, extending the clinical support"

Phase 2 primary efficacy readout medical

"including a Phase 2 primary efficacy readout of PALI-2108 for UC that is expected in the second half of 2027"

stock-based compensation financial

"including increased non-cash share-based compensation expense, as well as higher professional fees"

Stock-based compensation is when a company pays employees, directors or consultants with shares or the right to buy shares instead of or in addition to cash. It matters to investors because issuing stock or options spreads ownership thinner (like cutting a pie into more slices), which can reduce each existing share’s claim on profits and can also change reported earnings; investors watch it to assess true cost of running the business and how management is incentivized.

contingent consideration obligation financial

"Contingent consideration obligation | | | 271 | | | | 266 |"

Earnings Snapshot

Net loss: $9.6M

Q1 2026

Net loss $9.6M

Research and development expense $6.4M

General and administrative expense $4.4M

Cash and cash equivalents $132.6M

Understanding 8-K Material Events →

0001357459falseNONE00013574592026-05-122026-05-12

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): May 12, 2026

PALISADE BIO, INC.

(Exact name of Registrant as Specified in Its Charter)

Delaware			001-33672	52-2007292
(State or Other Jurisdiction of Incorporation)			(Commission File Number)	(IRS Employer Identification No.)
4600 South Syracuse Street Suite 900
Denver, Colorado				80237
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s Telephone Number, Including Area Code: (858) 704-4900

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.01 par value		PALI		Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On May 12, 2026, Palisade Bio, Inc. (the “Company”) issued a press release announcing its financial results for the three months ended March 31, 2026. The press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

The information in Item 2.02 of this Current Report on Form 8-K shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended. The information contained herein shall not be incorporated by reference into any filing with the Securities and Exchange Commission made by the Company, whether made before or after the date hereof, regardless of any general incorporation language in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number		Description
99.1		Palisade Bio, Inc. Press Release issued on May 12, 2026
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this Report on Form 8-K to be signed on its behalf by the undersigned hereunto duly authorized.

			PALISADE BIO, INC.
Date:	May 12, 2026	By:	/s/ J.D. Finley
			J.D. Finley Chief Executive Officer

EXHIBIT 99.1

Palisade Bio Reports First Quarter 2026 Financial Results and Highlights Continued Clinical Progress of PALI-2108

Advancing potentially best-in-class once-daily oral, locally-activated PDE4 inhibitor prodrug for treatment of IBD

Phase 2 Ulcerative Colitis (UC) trial expected to commence 3Q 2026

Strong balance sheet expected to support execution through key clinical readouts

Denver, CO, May 12, 2026 — Palisade Bio, Inc. (Nasdaq: PALI) (“Palisade Bio” or the “Company”), a clinical-stage biopharmaceutical company developing next-generation, once-daily, oral PDE4 inhibitor prodrugs designed for targeted delivery to the terminal ileum and colon, today reported financial results for the first quarter ended March 31, 2026 and highlighted continued clinical advancements of its lead program, PALI-2108, including recent data readouts and anticipated Phase 2 trial initiations.

Building on positive Phase 1a and Phase 1b ulcerative colitis cohort data previously reported, the Company recently reported results from the Phase 1b fibrostenotic Crohn’s disease (“FSCD”) cohort, extending the clinical support for the continued development of PALI-2108 across multiple inflammatory bowel disease (“IBD”) indications. The data demonstrated sustained exposure of the active metabolite above IC90 thresholds, along with favorable distribution to colon tissue, supporting consistent target engagement at the site of disease. In addition, pharmacodynamic findings showed modulation of key inflammatory and fibrotic pathways, reinforcing the potential of PALI-2108 to address both components of IBD. The program continues to demonstrate a favorable safety and tolerability profile, reinforcing confidence in the potential of PALI-2108 as it advances into Phase 2 development.

“We continue to see a consistent and differentiated profile emerging for PALI-2108 across IBD,” said JD Finley, Chief Executive Officer of Palisade Bio. “The totality of data generated to date supports our decision to advance into Phase 2 development in both ulcerative colitis and Crohn’s disease. With consistent target engagement, evidence of activity across key inflammatory and fibrotic pathways, and a favorable safety profile, we are increasingly confident in the potential of PALI-2108 as we move into development this year.”

EXHIBIT 99.1

Recent Highlights and Anticipated Milestones

•Completed Phase 1a/b for PALI-2108, Reported Positive Data

✓Favorable safety and tolerability profile

✓Evidence of target engagement in ileal and colon tissue

✓Early signals of clinical activity in Crohn’s disease

•Advancing Toward Phase 2

oIND submission for Phase 2 UC trial expected in 2Q 2026

oIND submission for Phase 2 CD trial expected in 2H 2026

oPhase 2 UC trial initiation targeted for Q3 2026

oPhase 2 CD trial initiation targeted for Q1 2027

•Well-Capitalized Through Potential Key Value Inflection Points

oPhase 2 UC readout (expected in 2H 2027)

oPhase 2 CD readout (expected early 2028)

PALI-2108 is an orally administered, once-daily PDE4 inhibitor prodrug designed for targeted activation in the ileum and colon. Its localized bioactivation is intended to enable sustained target inhibition at the site of inflammation while minimizing systemic exposure and improving tolerability.

Summary of Financial Results

Research and development expenses were $6.4 million for the three months ended March 31, 2026, compared to $1.0 million for the three months ended March 31, 2025. The increase of $5.4 million was primarily attributable to (i) an increase in research and development employee-related expenses, including increased non-cash share-based compensation expense, (ii) a net increase in clinical trial-related expenses associated with the ongoing clinical trials of PALI-2108, and (iii) an increase in chemistry, manufacturing and controls (“CMC”) expenses.

General and administrative expenses were $4.4 million for the three months ended March 31, 2026, compared to $1.4 million for the three months ended March 31, 2025. The increase of $3.0 million was primarily attributable to higher employee-related expenses, including increased non-cash share-based compensation expense, as well as higher professional fees.

As of March 31, 2026, the Company had cash and cash equivalents of $132.6 million and believes that its cash on hand is sufficient to fund its operations through major clinical development milestones, including a Phase 2 primary efficacy readout of PALI-2108 for UC that is expected in the second half of 2027 and a Phase 2 primary efficacy readout of PALI-2108 CD that is expected in early 2028.

EXHIBIT 99.1

About Palisade Bio

Palisade Bio, Inc. (Nasdaq: PALI) is a clinical-stage biopharmaceutical company advancing a next-generation oral PDE4 inhibitor prodrug designed to improve pharmacology, tolerability and convenience for patients with inflammatory and fibrotic diseases. Through its differentiated prodrug platform and precision pharmacology strategy, Palisade Bio is committed to transforming proven PDE4 biology into better, safer oral therapies for patients living with chronic inflammatory and fibrotic diseases.

The Company’s lead program, PALI-2108, is a once-daily oral PDE4 inhibitor prodrug designed to be selectively bioactivated in the ileum and colon, initiating targeted PDE4 inhibition at sites of disease while enabling systemic distribution of the active drug. PALI-2108 has demonstrated positive results in a Phase 1a and two Phase 1b clinical trials, including studies in ulcerative colitis (UC) and fibrostenotic Crohn’s Disease (FSCD).

Palisade Bio is now advancing towards Phase 2 clinical studies in UC and Crohn’s disease. For more information, please go to www.palisadebio.com.

Forward Looking Statements

Any statements contained in this communication that are not statements of historical fact may be deemed to be forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements include but are not limited to: the potential mechanisms of action and therapeutic benefits of PALI-2108, plans for and timing of regulatory submissions and approvals, clinical trials and efficacy readouts and the Company’s expected cash runway. These forward-looking statements are based on the Company’s current expectations. Forward-looking statements involve risks and uncertainties. Important factors that could cause actual results to differ materially from those reflected in the Company’s forward-looking statements include, among others, the timing of enrollment, commencement and completion of the Company’s clinical trials; the Company’s reliance on PALI-2108, and its early stage of clinical development; the risk that prior results, such as signals of safety, clinical response and efficacy, dosing or durability of effect, observed from preclinical or clinical trials with a limited number of patients, will not be replicated or will not continue in ongoing or future studies or clinical trials involving the Company’s product candidates in clinical trials focused on the same or different indications; and other factors that are described in the “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” sections of the Company’s Annual Report on Form 10-K for the fiscal year ended December 31,

EXHIBIT 99.1

2025, filed with the Securities and Exchange Commission (“SEC”) on March 20, 2026, and the Quarterly Reports on Form 10-Q or other SEC filings that are filed thereafter. Investors are cautioned not to put undue reliance on these forward-looking statements. These forward-looking statements speak only as of the date hereof, and the Company expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in the Company’s expectations with regard thereto or any change in events, conditions or circumstances on which any such statements are based, except as required by law.

Investor Relations Contact

JTC Team, LLC

Jenene Thomas

908-824-0775

PALI@jtcir.com

EXHIBIT 99.1

Palisade Bio, Inc.

Condensed Consolidated Bal ance Sheets (Unaudited)

(in thousands, except share and per share amounts)

		March 31,				December 31,
		2026				2025
ASSETS
Current assets:
Cash and cash equivalents		$	132,628			$	133,385
Prepaid expenses and other current assets			615				836
Total current assets			133,243				134,221
Restricted cash			55				55
Other noncurrent assets			17				68
Total assets		$	133,315			$	134,344
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable		$	2,696			$	767
Accrued liabilities			2,802				2,187
Accrued compensation and benefits			122				1,298
Share liability			—				313
Insurance financing debt			—				71
Total current liabilities			5,620				4,636
Derivative liability			62				62
Contingent consideration obligation			271				266
Total liabilities			5,953				4,964
Commitments and contingencies
Stockholders' equity:
Series A Convertible Preferred Stock, $0.01 par value, 7,000,000 shares authorized; 200,000 issued and outstanding at March 31, 2026 and December 31, 2025			2				2
Common stock, $0.01 par value; 300,000,000 shares authorized; 167,421,702 and 159,444,017 shares issued and outstanding at March 31, 2026 and December 31, 2025, respectively			1,674				1,594
Additional paid-in capital			288,011				280,509
Accumulated deficit			(162,325	)			(152,725	)
Total stockholders' equity			127,362				129,380
Total liabilities and stockholders' equity		$	133,315			$	134,344

EXHIBIT 99.1

Palisade Bio, Inc.

Condensed Consolidated Statements of Operations (Unaudited)

(in thousands, except share and per share amounts)

		Three Months Ended March 31,
		2026				2025
Operating expenses:
Research and development		$	6,397			$	950
General and administrative			4,351				1,360
Total operating expenses			10,748				2,310
Loss from operations			(10,748	)			(2,310	)
Other (expense) income:
Interest expense			(1	)			(1	)
Other income, net			1,149				81
Total other income, net			1,148				80
Net loss		$	(9,600	)		$	(2,230	)
Basic and diluted weighted average shares used in computing basic and diluted net loss per common share			209,663,966				4,795,646
Basic and diluted net loss per common share		$	(0.05	)		$	(0.47	)

EXHIBIT 99.1

Palisade Bio, Inc.

Condensed Consolidated Stateme nts of Cash Flows (Unaudited)

(in thousands)

		Three Months Ended March 31,
		2026				2025
Net loss		$	(9,600	)		$	(2,230	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation			—				1
Non-cash operating lease expense			—				31
Recurring fair value measurements of liabilities			5				(1	)
Stock-based compensation and related charges			4,297				69
Changes in operating assets and liabilities:
Prepaid and other current assets and other noncurrent assets			22				67
Accounts payable and accrued liabilities			2,562				366
Accrued compensation and benefits			(1,176	)			(604	)
Operating lease liabilities			—				(32	)
Net cash used in operating activities			(3,890	)			(2,333	)
Cash flows from financing activities:
Payments on insurance financing debt			(71	)			(80	)
Proceeds from issuance of common stock			3,250				—
Payment of equity issuance costs			(46	)			(178	)
Net cash provided by (used in) financing activities			3,133				(258	)
Net decrease in cash, cash equivalents and restricted cash			(757	)			(2,591	)
Cash, cash equivalents and restricted cash, beginning of year			133,440				9,847
Cash, cash equivalents and restricted cash, end of period		$	132,683			$	7,256
Reconciliation of cash, cash equivalents and restricted cash to the balance sheets:
Cash and cash equivalents		$	132,628			$	7,230
Restricted cash			55				26
Total cash, cash equivalents and restricted cash		$	132,683			$	7,256

FAQ

What did Palisade Bio (PALI) report for its Q1 2026 net loss?

Palisade Bio reported a net loss of $9.6 million for the quarter ended March 31, 2026, compared with $2.2 million in the prior-year period. The increase mainly reflects higher research and development and general and administrative expenses as PALI-2108 progresses clinically.

How much cash does Palisade Bio (PALI) have to fund PALI-2108 development?

As of March 31, 2026, Palisade Bio held $132.6 million in cash and cash equivalents. Management believes this is sufficient to fund operations through major clinical milestones, including Phase 2 primary efficacy readouts for PALI-2108 in ulcerative colitis and Crohn’s disease.

What are the planned Phase 2 trials for Palisade Bio’s PALI-2108?

Palisade Bio plans Phase 2 trials of PALI-2108 in ulcerative colitis and Crohn’s disease. The ulcerative colitis Phase 2 trial is targeted to start in Q3 2026, with the Crohn’s disease Phase 2 trial targeted for Q1 2027, following related IND submissions in 2026.

How did Palisade Bio’s R&D and G&A expenses change in Q1 2026?

Research and development expenses rose to $6.4 million in Q1 2026 from $1.0 million a year earlier. General and administrative expenses increased to $4.4 million from $1.4 million, reflecting higher employee-related costs, stock-based compensation and professional fees.

What clinical data has Palisade Bio reported for PALI-2108 so far?

Palisade Bio has completed Phase 1a and Phase 1b studies of PALI-2108, including ulcerative colitis and fibrostenotic Crohn’s disease cohorts. The data showed sustained active metabolite exposure above IC90 thresholds, favorable colon tissue distribution, modulation of inflammatory and fibrotic pathways, and a favorable safety profile.

When are key efficacy readouts for PALI-2108 expected for Palisade Bio?

The company expects a Phase 2 primary efficacy readout for PALI-2108 in ulcerative colitis in the second half of 2027. A Phase 2 primary efficacy readout for PALI-2108 in Crohn’s disease is anticipated in early 2028, supported by the current cash runway.

Filing Exhibits & Attachments

2 documents

Press Releases

• EX-99.1 EX-99.1 271.0 KB

Other Documents

• EX-101 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT 24.3 KB